Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)‘s stock had its “overweight” rating reiterated by equities researchers at J P Morgan Chase & Co in a research note issued on Wednesday. They currently have a $38.00 price target on the biotechnology company’s stock, up from their prior price target of $32.00. J P Morgan Chase & Co’s price objective would indicate a potential downside of 3.43% from the stock’s previous close.
Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 12th. ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research report on Tuesday, July 11th. Finally, Robert W. Baird lifted their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $36.00.
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded up 0.31% on Wednesday, reaching $39.35. The company had a trading volume of 182,046 shares. The company has a 50-day moving average price of $36.29 and a 200-day moving average price of $32.18. Enanta Pharmaceuticals has a 52-week low of $21.00 and a 52-week high of $39.81. The firm’s market capitalization is $750.92 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. The company had revenue of $7.51 million for the quarter, compared to the consensus estimate of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 7.69% and a negative net margin of 51.85%. The firm’s revenue was down 46.3% compared to the same quarter last year. During the same period last year, the business posted ($0.06) earnings per share. Equities research analysts forecast that Enanta Pharmaceuticals will post $0.54 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/10/enanta-pharmaceuticals-inc-nasdaqenta-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.
A number of large investors have recently added to or reduced their stakes in the stock. First Manhattan Co. increased its stake in Enanta Pharmaceuticals by 6.4% in the second quarter. First Manhattan Co. now owns 934,700 shares of the biotechnology company’s stock worth $33,630,000 after buying an additional 56,200 shares during the last quarter. Vanguard Group Inc. increased its stake in Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock worth $24,399,000 after buying an additional 53,007 shares during the last quarter. State Street Corp increased its stake in Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock worth $23,063,000 after buying an additional 180,586 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its stake in Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock worth $10,965,000 after buying an additional 120,000 shares during the last quarter. 65.95% of the stock is currently owned by institutional investors.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.